Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

053IC - Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management

Sunday, May 20
1:30 PM - 3:30 PM
Location: MCC WEST, 2004

A critical mass of data is accumulating for upper tract urothelial carcinoma (UTUC), yet the practicing urologist may not see this disease often enough in order to effectively assimilate the available data. This course will integrate available evidence and experience of high-volume experts, utilizing an interactive tumor board format to present cases that highlight evolving concepts, new and existing approaches, and dilemmas that are faced in everyday practice. Each case will focus on a particular important aspect of disease management and faculty will present the best available data. Aspects of management with little or low quality of evidence support will be discussed similar to a tumor board and with involvement of attendees.

Learning Objectives:

Surena F. Matin

Monteleone Family Foundation Endowed Professor, Department of Urology
MD Anderson Cancer Center

Cornell University Medical School. Internship, Residency, AFUD Research Fellow, and Clinical Fellowship all at Cleveland Clinic Foundation.
At MD Anderson Cancer Center since 2002, Professor with Tenure, endowed position with the Monteleone Family Foundation for Research in Kidney and Bladder Cancer. Primary clinical interests are UTUC, kidney cancer, and adrenal tumors. Primary research interest is UTUC clinical and genomic discovery. Medical Director of Minimally Invasive New Technology in Oncologic Surgery (MINTOS) collaborative program.


Send Email for Surena Matin

Wes Kassouf

McGill University Health Centre

Dr Wassim Kassouf completed a clinical and research fellowship in urologic oncology at M. D. Anderson Cancer Center in Houston, Texas following medical school and urology residency at McGill University. He then arrived back on faculty at the McGill University Health Center in 2006. Dr. Kassouf’s clinical practice focuses on all aspects of urologic oncology (including bladder, prostate, renal, and testes cancer) whereas his research focuses on bladder cancer. He is a Professor in the Division of Urology and Vice-Chair, academic affairs, of the Department of Surgery at McGill University. He has served as program director over the last 6 years and currently is a member of the Royal College Examination board committee.
He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 280 peer-review manuscripts and book chapters. He has obtained independent peer-reviewed grant funding from the CRS and CIHR. He is an associate editor for BMC Urology, and a section editor for CUAJ, and is/has been on the editorial board of Urology, Clinical Cancer Investigation Journal, and International Brazilian Journal of Urology. He is a course director on bladder and upper tract cancers at the SIU and AUA. He is the founder of the national Canadian Bladder Cancer Network, a cofounder of Bladder Cancer Canada, co-chair of the National Cancer Institute of Canada’s disease-oriented group in bladder cancer, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. Dr Kassouf is a graduate of the AUA Leadership Program and received several awards including the American Urological Association Young Urologist of the Year, AUA Research Scholar Award, Canadian Urological Association Scholarship Award, FRSQ Senior Clinician Scientist Research Scholar Award, and the Everett C. Reid Teaching Excellence Award.


Send Email for Wes Kassouf

Shahrokh Shariat

medical univ vienna

Dr. Shariat is currently professor and chairman of the department of urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, NY, adjunct professor of urology at the University of Texas Southwestern Medical Center, Dallas, TX, USA, and guest professor at the Faculty of Medicine, Charles University, Prague, CZ. He has published more than 900 peer-reviewed research papers (Scopus h-index 76, 23,553 citations; stand 12/2016), >200 non-peer-reviewed papers, and 18 book chapters. He is the holder of four patents stemming from his research into prostate and bladder cancer, and is the recipient of various national and international rewards. He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials. He is a member of various academic societies and a journal, meeting abstract, and grant reviewer for numerous national and international organizations. He is an editorial board member of various journals including European Urology, BJU International, World Journal of Urology, Current Opinion in Urology (editor in chief), and Immunotherapy among others. His research focuses on urologic oncology - molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research. Specially, Dr. Shariat's has been working on the discovery, testing, and validation of molecular markers associated with the biological and clinical behavior of prostate and urothelial cancers. His laboratory research focuses on integrative genomics and epigenomics of urothelial carcinoma with the goal of designing personalized therapeutic strategies.


Send Email for Shahrokh Shariat

Douglas Scherr

Weill Cornell Medical College-NY Presbyterian Hospital

Dr. Douglas Scherr is a Professor of Urology and the Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University in New York City.

Dr. Scherr received his undergraduate degree in Government at Cornell University. After a year teaching English in Shenyang, China, Dr. Scherr completed his medical training at The George Washington University School of Medicine in Washington, D.C. Following this he completed a 6 year residency in Urology at The New York Hospital-Cornell University Medical Center. Subsequently, Dr. Scherr then went on to pursue a Fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York for two years.

Dr. Scherr’s clinical focus is in the treatment of urologic malignancies. In particular, the treatment of prostate cancer, bladder cancer, kidney cancer, and testicular cancers, as well as genitourinary and retroperitoneal sarcomas. Dr. Scherr was the first physician at Cornell to perform a robotic prostatectomy in 2002, and he has since performed thousands of these procedures and travels nationally and internationally teaching the procedure to many urologic surgeons. Dr. Scherr has expanded his robotic practice in Manhattan to now include robotic-assisted removal of bladders with total bladder reconstructions.

In addition to his clinical responsibilities, Dr. Scherr also has an active role in the Laboratory of Urologic Oncology. Dr. Scherr has been instrumental in defining the hormonal regulation of bladder cancer and is now developing a novel class of compounds that utilize the innate immune system to fight urologic tumors. In addition, Dr. Scherr is now on the forefront in defining the role of the intestinal microbiome and its relationship to prostate cancer. Dr. Scherr is now engaged in work to reprogram immune cells to enhance their ability to engage tumor antigens.


Send Email for Douglas Scherr


053IC - Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management


Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management